|

SL-401 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Dana-Farber Cancer Institute1

Indications

  • Blastic Plasmacytoid Dendritic Cell Neoplasm1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1
  • Cancer1

Duarte, California1 trial

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

City of Hope

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.